Related Experiment Video
Updated: Feb 11, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
Evan F Garner1, Adele P Williams1, Laura L Stafman1
1Division of Pediatric Surgery, Department of Surgery, University of Alabama, Birmingham, Birmingham, AL, USA.
Abstract:
Group 3 tumors account for 28% of medulloblastomas and have the worst prognosis. FTY720, an immunosuppressant currently approved for treatment of multiple sclerosis, has shown antitumor effects in several human cancer cell lines. We hypothesized that treatment with FTY720 (fingolimod) would decrease tumorigenicity in medulloblastoma patient-derived xenografts (PDXs). Three Group 3 medulloblastoma PDXs (D341, D384 and D425) were utilized. Expression of PP2A and its endogenous inhibitors I2PP2A and CIP2A was detected by immunohistochemistry and immunoblotting. PP2A activation was measured via phosphatase activation kit. Cell viability, proliferation, migration and invasion assays were performed after treatment with FTY720. Cell cycle analysis was completed using flow cytometry. A flank model using D425 human medulloblastoma PDX cells was used to assess the in vivo effects of FTY720. FTY720 activated PP2A and led to decreased medulloblastoma PDX cell viability, proliferation, migration and invasion and G1 cell cycle arrest in all three PDXs. FTY720 treatment of mice bearing D425 medulloblastoma PDX tumors resulted in a significant decrease in tumor growth compared to vehicle treated animals. FTY720 decreased viability, proliferation, and motility in Group 3 medulloblastoma PDX cells and significantly decreased tumor growth in vivo. These results suggest that FTY720 should be investigated further as a potential therapeutic agent for medulloblastoma.
Insights
FTY720 (fingolimod) shows promise in treating Group 3 medulloblastoma. This drug decreased tumor cell growth, migration, and invasion in patient-derived xenografts, significantly reducing tumor size in vivo.
Area of Science:
- Oncology
- Pharmacology
Background:
- Group 3 medulloblastomas represent 28% of cases and have a poor prognosis.
- FTY720 (fingolimod), an established immunosuppressant, exhibits anticancer properties in various cell lines.
Purpose of the Study:
- To investigate the efficacy of FTY720 (fingolimod) in reducing the tumorigenicity of Group 3 medulloblastoma patient-derived xenografts (PDXs).
Main Methods:
- Utilized three Group 3 medulloblastoma PDXs (D341, D384, D425).
- Assessed PP2A expression and activation, cell viability, proliferation, migration, invasion, and cell cycle.
- Evaluated in vivo tumor growth in a flank model using D425 PDX cells.
Main Results:
- FTY720 activated PP2A, decreasing cell viability, proliferation, migration, and invasion in all three PDXs.
- Induced G1 cell cycle arrest in medulloblastoma cells.
- Significantly inhibited tumor growth in vivo in the D425 PDX flank model.
Conclusions:
- FTY720 demonstrates significant antitumor effects against Group 3 medulloblastoma PDX cells in vitro and in vivo.
- These findings support further investigation of FTY720 as a potential therapeutic agent for medulloblastoma.
Related Concept Videos
Decreasing Function
Decreased Body Temperature
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Measurement: Derived Units
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Higher Derivatives

